Halozyme Therapeutics, Inc.

NasdaqGS:HALO 株式レポート

時価総額:US$6.2b

Halozyme Therapeutics バランスシートの健全性

財務の健全性 基準チェック /36

Halozyme Therapeuticsの総株主資本は$452.7M 、総負債は$1.5Bで、負債比率は332.3%となります。総資産と総負債はそれぞれ$2.1Bと$1.7Bです。 Halozyme Therapeuticsの EBIT は$477.0Mで、利息カバレッジ比率60.1です。現金および短期投資は$666.3Mです。

主要情報

332.3%

負債資本比率

US$1.50b

負債

インタレスト・カバレッジ・レシオ60.1x
現金US$666.31m
エクイティUS$452.70m
負債合計US$1.67b
総資産US$2.12b

財務の健全性に関する最新情報

Recent updates

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Nov 20

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 05

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Oct 29
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics: Behind The Pullback

Oct 22

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Aug 13
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Jul 17
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Halozyme Therapeutics: The Story Brightens

Jun 07

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Apr 26
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Apr 10

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Apr 05
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09
We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28
Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

財務状況分析

短期負債: HALOの 短期資産 ( $1.1B ) が 短期負債 ( $108.8M ) を超えています。

長期負債: HALOの短期資産 ( $1.1B ) は 長期負債 ( $1.6B ) をカバーしていません。


デット・ツー・エクイティの歴史と分析

負債レベル: HALOの 純負債対資本比率 ( 185.1% ) は 高い と見なされます。

負債の削減: HALOの負債対資本比率は、過去 5 年間で26%から332.3%に増加しました。

債務返済能力: HALOの負債は 営業キャッシュフロー によって 十分にカバー されています ( 26.8% )。

インタレストカバレッジ: HALOの負債に対する 利息支払いEBIT ( 60.1 x coverage) によって 十分にカバーされています


貸借対照表


健全な企業の発掘